Career Center
Loading...
To ensure maximum visibility of your profile by employers, please be sure to update your profile with your current resume by going to your "Overview" page and then clicking on the "Post Your Resume" in the left column. This will walk you step by step through the set up process.
Hemolytic Anemia Sales Specialist, Rare Genetic Diseases
Agios Pharmaceuticals
Hiring Across Multiple Territories
Agios (agios.com) is a biopharmaceutical company committed to applying our scientific leadership in cellular metabolism to transform the lives of patients with cancer and rare genetic diseases. We are growing rapidly with an active research and discovery pipeline across both therapeutic areas. Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.
Our lead rare genetic disease program, Mitapivat, is in Phase 3 clinical development for the treatment of pyruvate kinase (PK) deficiency with positive topline results announced in early December that the first of two registration-enabling trials met its primary endpoint. Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes. Mutations in PKR cause deficiencies in red blood cell glycolysis, which lead to a disease known as PK deficiency. PK deficiency is an inherited disease that causes lifelong hemolytic anemia as well as other serious complications. Activation of wild-type PKR has potential utility in other hemolytic anemias such as thalassemia and sickle cell disease; Agios is currently evaluating Mitapivat in both disease areas and expects to initiate pivotal trials this year. The Hemolytic Anemia Specialist will report to a Regional Business Director, Rare Genetic Diseases, and will be a founding member of a new, best-in-class rare disease sales team. Each Hemolytic Anemia Specialist will be responsible for raising awareness of PKD across their respective geographies in anticipation of the initial US approval of Mitapivat for Pyruvate Kinase Deficiency (PKD).
We are seeking individuals with a demonstrated track record of success in launching rare diseases medicines and who are skilled at understanding the unique business drivers within their geography. The Hemolytic Anemia Specialists should possess a scrappy “start-up” mentality and values consistent with the patient and science focused Agios culture. They will be motivated by the opportunity to bring a rare disease commercialization mindset and to build their markets which will lay the foundation for the success of Mitapivat and Agios’ pipeline of transformative rare genetic disease treatments.
Key Responsibilities
Minimum Qualifications:
Preferred Qualifications:
Travel Requirements
|
Error
